Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT02560935
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 440 participants
- Sponsor
- Registry
-
NCT02560935
-
- Other papers using this trial's data
- Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial
- Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Nigeria
- Registry status
- Completed
Technical summary
Registry record NCT02560935. Randomized; double masking; primary purpose prevention. Start 2016-07-19 (actual); primary completion 2020-03-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
- Acronym
- SPRING
- Condition
- Sickle Cell Disease
- Condition
- Stroke
- Intervention (Drug)
- Hydroxyurea (Moderate Dose)
- Intervention (Drug)
- Hydroxyurea (Low Dose)
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- Aminu Kano Teaching Hospital
- Collaborator
- Murtala Muhammed Specialist Hospital
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Barau Dikko Teaching Hospital/Kaduna State University
Record details
- Record id
cardio:ct-nct02560935- Content hash
c6833fcc887f47aafb68cb209a6929a1d36434c785caf6961488fb7a6a2a188a